Edition:
United Kingdom

Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

1.62USD
21 Nov 2017
Change (% chg)

$-0.02 (-1.22%)
Prev Close
$1.64
Open
$1.64
Day's High
$1.72
Day's Low
$1.56
Volume
88,463
Avg. Vol
28,578
52-wk High
$5.69
52-wk Low
$1.56

Chart for

About

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management... (more)

Overall

Beta: 2.39
Market Cap(Mil.): $31.79
Shares Outstanding(Mil.): 15.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.23 16.44
EPS (TTM): -- -- --
ROI: -- 2.53 10.62
ROE: -- 3.17 14.20

BRIEF-Orexigen Therapeutics Q3 loss per share $1.35

* Orexigen Therapeutics announces third quarter 2017 financial results

13 Nov 2017

BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt

* Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America

13 Nov 2017

BRIEF-Orexigen Therapeutics - pursuing potential actions including merger or sale of co

* Orexigen Therapeutics Inc says ‍expects total revenues for Q3 of 2017 to be between about $18.1 million and $19.1 million-SEC filing​

16 Oct 2017

BRIEF-Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030

* Orexigen announces favorable decision from U.S. District Court in patent litigation, confirming exclusivity for Contrave through 2030

13 Oct 2017

BRIEF-Orexigen Therapeutics sees 2017 net sales $85 mln to $100 mln - presentation slides‍​

* Orexigen Therapeutics Inc sees Orexigen net sales $85 million to $100 million for 2017 - presentation slides‍​ Source text: (http://bit.ly/2fpwCRS) Further company coverage:

26 Sep 2017

BRIEF-Orexigen Therapeutics to provide business update

* Orexigen Therapeutics to provide business update at the 2017 Cantor Fitzgerald Global Healthcare Conference Source text for Eikon: Further company coverage:

13 Sep 2017

BRIEF-Orexigen Therapeutics Q2 loss per share $2.00

* Orexigen Therapeutics announces second quarter 2017 financial results

08 Aug 2017

BRIEF-Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria

* Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria

07 Aug 2017

BRIEF-Orexigen Therapeutics announces expansion of distributorship agreement with Biologix FZCO for Contrave to Egypt

* Orexigen Therapeutics announces expansion of distributorship agreement with Biologix FZCO for Contrave® (naltrexone hcl / bupropion hcl extended release) to Egypt

26 Jul 2017

Earnings vs. Estimates